B. Riley reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Thursday morning. They currently have a $11.25 target price on the medical research company’s stock.

Several other research analysts have also recently weighed in on CTSO. ValuEngine cut shares of Cytosorbents from a hold rating to a sell rating in a research report on Monday, October 2nd. Maxim Group set a $12.00 price target on shares of Cytosorbents and gave the company a buy rating in a research report on Thursday, October 19th. Finally, HC Wainwright reissued a buy rating and set a $13.00 price target on shares of Cytosorbents in a research report on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $10.65.

Cytosorbents (CTSO) opened at $7.60 on Thursday. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73. The firm has a market cap of $216.63, a PE ratio of -20.00 and a beta of -0.54. Cytosorbents has a 1 year low of $3.30 and a 1 year high of $7.90.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). Cytosorbents had a negative net margin of 67.83% and a negative return on equity of 233.72%. analysts expect that Cytosorbents will post -0.26 earnings per share for the current year.

In related news, COO Vincent Capponi sold 4,000 shares of the business’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the chief operating officer now directly owns 271,062 shares in the company, valued at approximately $1,897,434. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kathleen P. Bloch sold 32,400 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $7.30, for a total transaction of $236,520.00. Following the completion of the sale, the chief financial officer now owns 248,638 shares in the company, valued at $1,815,057.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,800 shares of company stock worth $360,620. 5.60% of the stock is owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Fortaleza Asset Management Inc. raised its holdings in Cytosorbents by 81.6% in the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after buying an additional 10,500 shares during the period. PNC Financial Services Group Inc. raised its holdings in Cytosorbents by 145.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in Cytosorbents in the 3rd quarter valued at about $365,000. Finally, Skylands Capital LLC raised its holdings in Cytosorbents by 45.1% in the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after buying an additional 225,558 shares during the period. Hedge funds and other institutional investors own 9.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/b-riley-reiterates-buy-rating-for-cytosorbents-ctso/1829398.html.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.